ArticleBMC neurology2025
Efgartigimod therapy for immune checkpoint inhibitor-associated myasthenia gravis with myositis: a case report.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efgartigimod as Rescue Therapy for PD-1 Inhibitor-Associated Myasthenia Gravis, Myocarditis, and Myositis (MMM) Syndrome: A 2-Case Report and Literature Review.The American journal of case reports · 2026Review
- Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The advent of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but their association with immune-related adverse events presents a new and complex challenge for clinicians. In this report, we present the case of a 60-year-old Han Chinese woman who developed myasthenia gravis (MG) with myositis after pembrolizumab treatment for breast cancer. The patient presented with ptosis, slurred speech, limb weakness, and ocular fixation. Her creatine kinase level was elevated but she reported no muscle pain. The patient was diagnosed with ICI-associated MG with myositis. Before presenting to us, the patient had received low doses of intravenous methylprednisolone followed by oral prednisone, but her symptoms had continued to worsen. Her muscle strength improved significantly after we treated her with efgartigimod. This report is the first description of efgartigimod use in the treatment of ICI-associated MG with myositis, a new strategy for the treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.